广佛手药材HPLC指纹图谱的研究

目的建立广佛手药材HPLC指纹图谱,以便比较完整地反映广佛手的内在化学信息,全面评价广佛手药材质量,与其他产地佛手进行鉴别。方法应用HPLC法测定了12批佛手的指纹图谱,乙腈-0.5%冰醋酸为流动相进行梯度洗脱,检测波长290nm,体积流量1.0mL/min,柱温30℃,收集75min。结果建立了广佛手HPLC指纹图谱共有模式,并对不同产地药材进行了相似度比较。结论该方法稳定可靠,信息量大,为广佛手药材鉴别和质量评价提供了依据。     

三七开花习性观察

本文报道了在云南省文山州气候条件下三七的开花、散粉规律，可为三七的杂交育种工作提供依据。     

调肝与健脾对节育器致人子宫异常出血症子宫内膜组织ERK1/2、PI_3K信号通路的影响差异

目的:探讨柴胡止血液对置器后子宫异常出血患者的影响机制。方法:原代培养置器后子宫异常出血患者的宫内膜组织,给含药血清后,分别采用western blot和ELISA的方法测定ERK1/2和PI3K磷酸化的水平。结果:4号组织的归脾汤组升高了PI3K磷酸化水平,P<0.05;1号组织的柴胡止血液组有升高ERK1/2磷酸化水平的趋势;3号组织的柴胡止血液组有升高ERK1/2磷酸化水平的趋势;5号组织的柴胡止血液组有升高PI3K磷酸化水平的趋势;2号组织的归脾汤组有升高ERK1/2磷酸化水平的趋势;4号组织的归脾汤组有升高ERK1/2和PI3K磷酸化水平的趋势。结论:对于出血量大的肝旺患者,柴胡止血液可能通过激活ERK1/2通路来增强血管的收缩从而达到止血的目的;对于出血量较小的肝旺患者证,柴止血液可能通过激活PI3K通路来调节组织抗炎作用,从而达到治疗效果。     

中药代谢分析研究进展＊

中药具有多成分、多靶点的特性，药效物质基础及药物代谢途径不明确严重制约中药的发展。中药小分子经过体内代谢后转化成代谢物发挥药效或者清除。近年来随着MS技术的飞速发展，通过LC-MS技术进行精准定性定量分析，以阐明中药代谢物与机体生理及病理相关变化的关系，从而明确中药的药效物质基础及体内代谢路径。本文从中药代谢研究思路、研究方法、影响因素以及应用等方面，就近年来中药代谢分析领域的研究进展进行综述。     

脊髓纵裂的手术疗效观察

收治脊髓纵裂４６例，其中２９例作神经功能状态的临床评价及胫后神经皮层体感诱发电位检查。结果：非手术组随访后神经功能缺陷无改善（Ｐ＞０．０５）；２０例手术组神经功能的临床评分明显增加及胫后神经皮层体感诱发电位明显改善（Ｐ＜０．０５）。表明手术不仅可阻止神经功能缺陷的发展，而且可使其得到改善，是一有效的治疗手段。     

Leflunomide therapy for adult patients with steroid-dependent minimal change disease or primary focal segmental glomerulosclerosis

<正>     

姬松茸多糖与OVA共同免疫改善E.G7-OVA荷瘤小鼠免疫功能的研究

目的通过小鼠体内免疫的方法,观察姬松茸多糖与模型肿瘤抗原卵清白蛋白(OVA)共同免疫对E.G7-OVA荷瘤小鼠免疫功能的影响。方法姬松茸多糖(高、中、低剂量)与OVA共同免疫E.G7-OVA荷瘤小鼠,观察其对EG7荷瘤小鼠脾指数、胸腺指数以及小鼠外周血中T淋巴细胞亚群CD4+和CD8+比例的影响。结果姬松茸多糖(高、中剂量)与OVA共同免疫组小鼠的脾指数、胸腺指数明显大于单独使用OVA组,外周血中CD4+/CD8+T细胞比值也有明显升高。结论姬松茸多糖能够辅助OVA改善EG7-OVA荷瘤小鼠的免疫功能状态,姬松茸多糖可能作为免疫佐剂用于肿瘤的预防与治疗。     

丹参酮提取物物理化学质量属性相关性分析

目的：探寻丹参酮提取物化学成分的含量与物理性质之间的相关性。方法：HPLC测定50批丹参酮提取物中隐丹参酮、丹参酮IIA的含量,经典方法测定物理性质,将成分含量与物理性质进行相关性分析。结果：两变量组组内的隐丹参酮与丹参酮IIA含量,D10、D50、D90 之间,松装密度与振实密度,豪斯纳比率与压缩度指数均具有较强的相关性,休止角与均齐度、豪斯纳比率、压缩度指数具有一定的相关性,但相关性不强。两变量组的原始变量组间相关性系数最大不超过0.400,相关性不强。经过典型相关分析,3对典型变量的相关性显著,相关系数分别为0.851,0.674,0.565。结论：对于丹参酮提取物的化学、物理质量属性,原始变量组内具有较好的相关性,但组间相关性较差。相比原始变量,典型变量呈现出了较好的组间相关性,表明丹参酮提取物的物理化学属性之间具有一定的相关性。     

Rituximab for the treatment of refractory anti-glomerular basement membrane disease

BackgroundAnti-glomerular basement membrane (anti-GBM) disease is a rare but severe autoantibody-mediated immune disorder. The typical clinical presentation includes rapidly progressive glomerulonephritis and often concurrent pulmonary hemorrhage. The present study is aimed to investigate the therapeutic effects of rituximab either used alone or with other immunosuppressants.MethodsEight patients diagnosed with anti-GBM disease and treated with rituximab from 2014 to 2020 were retrospectively reviewed.ResultsEight patients included 5 males and 3 females with a median age of 58.5 years. They all presented severe kidney injuries and 1 patient had lung hemorrhage. At diagnosis, the median of serum creatinine was 246 µmol/L (ranging from 91 to 850 µmol/L), with 3 patients requiring dialysis. All of them received corticosteroids and plasmapheresis. Rituximab was given as either standard four weekly doses or one pulse ranging from 100 to 600 mg. After a median follow-up of 34.5 months, kidney function was partially recovered or stabilized in 5/8 (62.5%) patients, free of dialysis. Anti-GBM antibodies remained undetected in all patients during follow-up. No severe adverse effect associated with rituximab was observed.ConclusionRituximab may be an alternative therapy in the treatment of patient with severe or refractory anti-GBM disease.     

Functional Fiber Reduces Mice Obesity by Regulating Intestinal Microbiota

Obesity may cause metabolic syndrome and has become a global public health problem, and dietary fibers (DF) could alleviate obesity and metabolic syndrome by regulating intestinal microbiota. We developed a functional fiber (FF) with a synthetic mixture of polysaccharides, high viscosity, water-binding capacity, swelling capacity, and fermentability. This study aimed to investigate the effect of FF on obesity and to determine its prevention of obesity by modulating the gut microbiota. Physiological, histological, and biochemical parameters, and gut microbiota composition were investigated in the following six groups: control group (Con), high-fat diet group (HFD), low-fat diet group (LFD, conversion of HFD to LFD), high-fat +8% FF group (8% FF), high-fat +12% FF group (12% FF), and high-fat +12% FF + antibiotic group (12% FF + AB). The results demonstrated that 12% FF could promote a reduction in body weight and epididymal adipocyte area, augment insulin sensitivity, and stimulate heat production from brown adipose tissue (BAT) (p < 0.05). Compared with the HFD, 12% FF could also significantly improve the intestinal morphological integrity, attenuate systemic inflammation, promote intestinal microbiota homeostasis, and stabilize the production of short-chain fatty acids (SCFAs) (p < 0.05). Consistent with the results of 12% FF, the LFD could significantly reduce the body weight and epididymal adipocyte area relative to the HFD (p < 0.05), but the LFD and HFD showed no significant difference (p > 0.05) in the level of inflammation and SCFAs. Meanwhile, 12% FF supplementation showed an increase (p < 0.05) in the abundance of the Bifidobacterium, Lactococcus, and Coprococcus genus in the intestine, which had a negative correlation with obesity and insulin resistance. Additionally, the treatment with antibiotics (12% FF + AB) could inhibit the effect of FF in the HFD. The Kyoto Encyclopedia of Genes and Genomes (KEGG) function prediction revealed that 12% FF could significantly inhibit the cyanogenic amino acid metabolic pathway and decrease the serum succinate concentration relative to the HFD group. The overall results indicate that 12% FF has the potential to reduce obesity through the beneficial regulation of the gut microbiota and metabolites.